RxDoctor Payments Data

Eddie Abdalla, MD

Surgical Oncology · Atlanta, GANPI 1235225889

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $21,600 of the $33,647 with a category attached, or 64.2%. Sirtex Medical Inc accounts for 81.1% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2023 at $20,579 and has fallen 98.1% since, to $382 in 2025. Among surgical oncology clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$33,647in general payments, 2019–2025

Across 126 payments — averaging $267.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sirtex Medical Inc$27K
  • Intuitive Surgical$3K
  • Angiodynamics, Inc.$1K
  • Boston Scientific$633
  • Johnson & Johnson$449
  • AbbVie$440
  • plus $757 from 11 others

What the payments were for

  • Consulting fees$1,0003%
  • Speaking & faculty fees$21,60064%
  • Travel & lodging$6,14618%
  • Food & beverage$4,90215%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$33,647 in reported general payments places this provider in the 95th percentile of 43 surgical oncology providers in Georgia.

See all surgical oncology providers in Georgia

Medicare billing

Part B allowed, 2024
$102,872
Medicare patients
97
Services billed
198

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase69$237,913
Pantoprazole Sodium43$393
Tramadol Hcl27$76

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon$440$237,91369 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 43 surgical oncology providers in Georgia.

Other surgical oncology in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →